Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design
Compose a Response to This Article
Other responses
No responses have been published for this article.
